EQL PHARMA AB Tangible Net Worth Ratio
EQL PHARMA AB tangible net worth ratio. EQL PHARMA AB (7JK) has a Tangible Net Worth Ratio of -65.2% as of March 2026. This metric is calculated by deducting intangible assets (€441.11 Million) from net assets (€267.06 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 7JK year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of EQL PHARMA AB (2022–2026)
Tangible net worth ratio of EQL PHARMA AB from 2022 to 2026. This chart shows how EQL PHARMA AB's Tangible Net Worth Ratio has changed across 5 annual periods from 2022 to 2026. As of March 2026, the ratio stands at -65.2%, reflecting net assets of €267.06 Million with intangible assets of €441.11 Million EUR.
EQL PHARMA AB Tangible Net Worth Ratio by Year (2022–2026)
EQL PHARMA AB tangible net worth ratio by year from 2022 to 2026. The table below presents the year-by-year Tangible Net Worth Ratio for EQL PHARMA AB from 2022 to 2026, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 7JK market cap overview.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2026 | -65.2% | €267.06 Million | €441.11 Million | €850.89 Million | ▲ +16.8 pp |
| 2025 | -82.0% | €221.03 Million | €402.25 Million | €808.82 Million | ▼ -84.5 pp |
| 2024 | 2.5% | €177.73 Million | €173.31 Million | €373.76 Million | ▼ -23.0 pp |
| 2023 | 25.5% | €154.75 Million | €115.32 Million | €285.70 Million | ▲ +14.7 pp |
| 2022 | 10.8% | €123.63 Million | €110.24 Million | €237.89 Million | — |